{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:53:51Z","timestamp":1777312431536,"version":"3.51.4"},"reference-count":36,"publisher":"Hamad bin Khalifa University Press (HBKU Press)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by a dysregulated immune response against self-antigen, leading to multi-organ involvement. Myositis, as an initial manifestation of SLE, is a rare clinical entity, particularly in newly diagnosed patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Case Presentation:<\/jats:bold>\n                    A 27-year-old male presented with massive head and neck swelling, initially suspected to be superior vena cava syndrome (SVCS). Other symptoms included non-scarring alopecia, prolonged fever, oral ulcers, a history of hyperpigmented skin lesions, and progressive lower extremity weakness with edema. Hematological findings revealed persistent pancytopenia (anemia, leukopenia, and thrombocytopenia). Laboratory investigations demonstrated elevated muscle injury markers, including aspartate aminotransferase predominance and elevated creatine kinase. Immunological analysis showed a negative antinuclear antibody by indirect immunofluorescence, high anti-dsDNA titers, and normal complement levels. Bone marrow biopsy revealed trilineage dysplasia with macrophage activation, suggesting underlying hematologic involvement. Contrast-enhanced head and neck computed tomography ruled out SVCS, showing only diffuse muscle and subcutaneous edema. Based on the constellation of clinical, hematological, and imaging findings, the patient was diagnosed with myositis-associated SLE. The therapeutic approach included total plasma exchange (TPE), high-dose corticosteroid pulse therapy, and immunosuppressive induction therapy. Within 1 month of hospitalization, the patient demonstrated significant clinical and laboratory improvement and was subsequently transitioned to maintenance therapy with hydroxychloroquine (200 mg once daily), methylprednisolone (8 mg daily in a tapering regimen), and mycophenolate mofetil (500 mg twice daily). The patient achieved a lupus low disease activity state at follow-up.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Discussion:<\/jats:bold>\n                    This case represents a unique presentation of head and neck myositis in a newly diagnosed SLE patient, a manifestation not previously described in the literature. While orbital myositis in SLE has been reported, extensive myositis involving the head and neck as an initial SLE manifestation remains undocumented. Combining TPE, high-dose corticosteroids, and immunosuppressants was critical in disease control. Early recognition and aggressive immunomodulatory therapy are essential in managing such rare and severe SLE presentations.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This case highlights an uncommon initial manifestation of SLE, emphasizing the importance of early clinical suspicion, comprehensive immunological and hematological evaluation, and prompt intervention. A multimodal therapeutic approach, including steroid pulse therapy, induction immunosuppression, and TPE, can lead to favorable clinical outcomes in severe and atypical SLE presentations.\n                  <\/jats:p>","DOI":"10.5339\/qmj.2025.65","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T09:30:43Z","timestamp":1756891843000},"source":"Crossref","is-referenced-by-count":0,"title":["Rare head and neck myositis with reversible myelodysplastic syndrome: The first reported lupus manifestation as an initial symptom"],"prefix":"10.5339","volume":"2025","author":[{"given":"Ayu","family":"Paramaiswari","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Fakhrur","family":"Rozi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gede Perdana","family":"Putera","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kartika","family":"Widayati","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia*Correspondence: Muhammad Fakhrur Rozi muhammadfakhrurrozi1993@mail.ugm.ac.id"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3277","reference":[{"issue":"(1):","key":"CIT0001","series-title":"Semin Arthritis Rheum","first-page":"43\u20138","article-title":"From incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers","volume":"51","author":"Lambers\n \nWM","year":"2021;","unstructured":"Lambers\n \nWM\n\n, \n\nWestra\n \nJ\n\n, \n\nBootsma\n \nH\n\n, \n\nde Leeuw\n \nK\n\n\n. \nFrom incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers\n. \nSemin Arthritis Rheum\n. \n2021;\n51\n(1):\n43\u20138\n. \nhttps:\/\/doi.org\/10.1016\/j.semarthrit.2020.11.006"},{"issue":"(6):","key":"CIT0002","series-title":"J Clin Investig","first-page":"2228\u201333","article-title":"Mechanisms of human autoimmunity","volume":"125","author":"Rosenblum\n \nMD","year":"2015;","unstructured":"Rosenblum\n \nMD\n\n, \n\nRemedios\n \nKA\n\n, \n\nAbbas\n \nAK\n\n\n. \nMechanisms of human autoimmunity\n. \nJ Clin Investig\n. \n2015;\n125\n(6):\n2228\u201333\n. \nhttps:\/\/doi.org\/10.1172\/JCI78088"},{"issue":"(7):","key":"CIT0003","series-title":"Clin Rheumatol","first-page":"1819\u201326","article-title":"Negative ANA-IIF in SLE patients: what is beyond?","volume":"42","author":"Abozaid\n \nHSM","year":"2023;","unstructured":"Abozaid\n \nHSM\n\n, \n\nHefny\n \nHM\n\n, \n\nAbualfadl\n \nEM\n\n, \n\nIsmail\n \nMA\n\n, \n\nNoreldin\n \nAK\n\n, \n\nEldin\n \nANN\n\n, \n\n\n \nNegative ANA-IIF in SLE patients: what is beyond?\n \nClin Rheumatol\n. \n2023;\n42\n(7):\n1819\u201326\n. \nhttps:\/\/doi.org\/10.1007\/s10067-023-06577-w"},{"issue":"(1):","key":"CIT0004","series-title":"Lupus Sci Med","first-page":"e000635","article-title":"Clinical and histopathological features of myositis in systemic lupus erythematosus","volume":"9","author":"Tiniakou\n \nE","year":"2022;","unstructured":"Tiniakou\n \nE\n\n, \n\nGoldman\n \nD\n\n, \n\nCorse\n \nA\n\n, \n\nMammen\n \nA\n\n, \n\nPetri\n \nMA\n\n\n. \nClinical and histopathological features of myositis in systemic lupus erythematosus\n. \nLupus Sci Med\n. \n2022;\n9\n(1):\ne000635\n. \nhttps:\/\/doi.org\/10.1136\/lupus-2021-000635"},{"key":"CIT0005","series-title":"Arthritis Rheumatol","first-page":"2868\u201370","article-title":"Prevalence and associations of myositis in an Indian inception cohort of lupus","volume":"74","author":"Rajasekhar\n \nL","year":"2022;","unstructured":"Rajasekhar\n \nL\n\n, \n\nShobha\n \nV\n\n, \n\nPonnana\n \nM\n\n, \n\nKavadichanda\n \nC\n\n, \n\nMathew\n \nAJ\n\n, \n\nTripathy\n \nSR\n\n, \n\n\n \nPrevalence and associations of myositis in an Indian inception cohort of lupus\n. \nArthritis Rheumatol\n. \n2022;\n74\n: \n2868\u201370\n."},{"issue":"(10):","key":"CIT0006","series-title":"Br J Rheumatol","first-page":"1067\u201374","article-title":"Clinical features of lupus myositis versus idiopathic myositis: a review of 30 cases","volume":"36","author":"Garton\n \nM","year":"1997;","unstructured":"Garton\n \nM\n\n, \n\nIsenberg\n \nD\n\n\n. \nClinical features of lupus myositis versus idiopathic myositis: a review of 30 cases\n. \nBr J Rheumatol\n. \n1997;\n36\n(10):\n1067\u201374\n. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/36.10.1067"},{"issue":"(4):","key":"CIT0007","series-title":"Eur J Rheumatol","first-page":"148","article-title":"Infections in patients with systemic lupus erythematosus: the contribution of primary immune defects versus treatment-induced immunosuppression","volume":"10","author":"Kunzler\n \nALF","year":"2023;","unstructured":"Kunzler\n \nALF\n\n, \n\nTsokos\n \nGC\n\n\n. \nInfections in patients with systemic lupus erythematosus: the contribution of primary immune defects versus treatment-induced immunosuppression\n. \nEur J Rheumatol\n. \n2023;\n10\n(4):\n148\n. \nhttps:\/\/doi.org\/10.5152\/eurjrheum.2023.23068"},{"issue":"(10):","key":"CIT0008","series-title":"Clin Rheumatol","first-page":"2995\u20133003","article-title":"Evaluation of the 2019 EULAR\/ACR classification criteria for systemic lupus erythematosus in children and adults","volume":"41","author":"Cheng\n \nS","year":"2022;","unstructured":"Cheng\n \nS\n\n, \n\nDing\n \nH\n\n, \n\nXue\n \nH\n\n, \n\nCao\n \nL\n\n\n. \nEvaluation of the 2019 EULAR\/ACR classification criteria for systemic lupus erythematosus in children and adults\n. \nClin Rheumatol\n. \n2022;\n41\n(10):\n2995\u20133003\n. \nhttps:\/\/doi.org\/10.1007\/s10067-022-06293-x"},{"key":"CIT0009","series-title":"Pediatr Rheumatol","first-page":"1\u20138","article-title":"Evaluating the performance of ACR, SLICC and EULAR\/ACR classification criteria in childhood onset systemic lupus erythematosus","volume":"19","author":"Abdwani\n \nR","year":"2021;","unstructured":"Abdwani\n \nR\n\n, \n\nMasroori\n \nE\n\n, \n\nAbdullah\n \nE\n\n, \n\nAl Abrawi\n \nS\n\n, \n\nAl-Zakwani\n \nI\n\n\n. \nEvaluating the performance of ACR, SLICC and EULAR\/ACR classification criteria in childhood onset systemic lupus erythematosus\n. \nPediatr Rheumatol\n. \n2021;\n19\n: \n1\u20138\n. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/keab247.118"},{"issue":"(1):","key":"CIT0010","series-title":"Ann Rheum Dis","first-page":"14\u201325","article-title":"Update on the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis\n \nA","year":"2021;","unstructured":"Fanouriakis\n \nA\n\n, \n\nTziolos\n \nN\n\n, \n\nBertsias\n \nG\n\n, \n\nBoumpas\n \nDT\n\n\n. \nUpdate on the diagnosis and management of systemic lupus erythematosus\n. \nAnn Rheum Dis\n. \n2021;\n80\n(1):\n14\u201325\n. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2020-218272"},{"issue":"(11):","key":"CIT0011","series-title":"Autoimmun Rev","first-page":"102943","article-title":"Systematic review of anti-dsDNA testing for systemic lupus erythematosus: a meta-analysis of the diagnostic test specificity of an anti-dsDNA fluorescence enzyme immunoassay","volume":"20","author":"Orme\n \nME","year":"2021;","unstructured":"Orme\n \nME\n\n, \n\nVoreck\n \nA\n\n, \n\nAksouh\n \nR\n\n, \n\nRamsey-Goldman\n \nR\n\n, \n\nSchreurs\n \nMWJ\n\n\n. \nSystematic review of anti-dsDNA testing for systemic lupus erythematosus: a meta-analysis of the diagnostic test specificity of an anti-dsDNA fluorescence enzyme immunoassay\n. \nAutoimmun Rev\n. \n2021;\n20\n(11):\n102943\n. \nhttps:\/\/doi.org\/10.1016\/j.autrev.2021.102943"},{"issue":"(5):","key":"CIT0012","series-title":"Neuroophthalmology","first-page":"264\u20137","article-title":"Systemic lupus erythematosus presenting as orbital myositis","volume":"38","author":"Jenkins\n \nPO","year":"2014;","unstructured":"Jenkins\n \nPO\n\n, \n\nSoper\n \nC\n\n, \n\nMacKinnon\n \nAD\n\n, \n\nO\u2019Sullivan\n \nE\n\n, \n\nNitkunan\n \nA\n\n\n. \nSystemic lupus erythematosus presenting as orbital myositis\n. \nNeuroophthalmology\n. \n2014;\n38\n(5):\n264\u20137\n. \nhttps:\/\/doi.org\/10.3109\/01658107.2014.923915"},{"issue":"(3):","key":"CIT0013","series-title":"Eur J Rheumatol","first-page":"135\u20137","article-title":"Orbital myositis in systemic lupus erythematosus: a case report and literature review","volume":"7","author":"Chan\n \nAJ","year":"2020;","unstructured":"Chan\n \nAJ\n\n, \n\nRai\n \nAS\n\n, \n\nLake\n \nS\n\n\n. \nOrbital myositis in systemic lupus erythematosus: a case report and literature review\n. \nEur J Rheumatol\n. \n2020;\n7\n(3):\n135\u20137\n \nhttps:\/\/doi.org\/10.5152\/eurjrheum.2020.19217"},{"issue":"(1047):","key":"CIT0014","series-title":"Postgrad Med J","first-page":"59","article-title":"Orbital myositis as manifestation of systemic lupus erythematosus-a case report","volume":"89","author":"Santosa\n \nA","year":"2013;","unstructured":"Santosa\n \nA\n\n, \n\nVasoo\n \nS\n\n\n. \nOrbital myositis as manifestation of systemic lupus erythematosus-a case report\n. \nPostgrad Med J\n. \n2013;\n89\n(1047):\n59\n. \nhttps:\/\/doi.org\/10.2169\/internalmedicine.47.0607"},{"issue":"(8):","key":"CIT0015","series-title":"Intern Med","first-page":"737\u201342","article-title":"Reversible bone marrow dysplasia in patients with systemic lupus erythematosus","volume":"47","author":"Oka\n \nY","year":"2008;","unstructured":"Oka\n \nY\n\n, \n\nKameoka\n \nJ\n\n, \n\nHirabayashi\n \nY\n\n, \n\nTakahashi\n \nR\n\n, \n\nIshii\n \nT\n\n, \n\nSasaki\n \nT\n\n, \n\n\n. \nReversible bone marrow dysplasia in patients with systemic lupus erythematosus\n. \nIntern Med\n. \n2008;\n47\n(8):\n737\u201342\n. \nhttps:\/\/doi.org\/10.2169\/internalmedicine.47.0607"},{"issue":"(2):","key":"CIT0016","series-title":"Hemato","first-page":"329\u201346","article-title":"Inflammatory and immune disorders associated with myelodysplastic syndromes","volume":"2","author":"Jachiet\n \nV","year":"2021;","unstructured":"Jachiet\n \nV\n\n, \n\nFenaux\n \nP\n\n, \n\nSevoyan\n \nA\n\n, \n\nHakobyan\n \nY\n\n, \n\nAdes\n \nL\n\n, \n\nFain\n \nO\n\n, \n\n\n. \nInflammatory and immune disorders associated with myelodysplastic syndromes\n. \nHemato\n. \n2021;\n2\n(2):\n329\u201346\n. \nhttps:\/\/doi.org\/10.3390\/hemato2020019"},{"issue":"(3):","key":"CIT0017","series-title":"Immunology","first-page":"153\u201360","article-title":"Infectious processes and systemic lupus erythematosus","volume":"158","author":"Illescas-Montes\n \nR","year":"2019;","unstructured":"Illescas-Montes\n \nR\n\n, \n\nCorona-Castro\n \nCC\n\n, \n\nMelguizo-Rodr\u00edguez\n \nL\n\n, \n\nRuiz\n \nC\n\n, \n\nCostela-Ruiz\n \nVJ\n\n\n. \nInfectious processes and systemic lupus erythematosus\n. \nImmunology\n. \n2019;\n158\n(3):\n153\u201360\n. \nhttps:\/\/doi.org\/10.1111\/imm.13103"},{"issue":"(1):","key":"CIT0018","series-title":"Ann Rheum Dis","first-page":"15\u201329","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis\n \nA","year":"2024;","unstructured":"Fanouriakis\n \nA\n\n, \n\nKostopoulou\n \nM\n\n, \n\nAndersen\n \nJ\n\n, \n\nAringer\n \nM\n\n, \n\nArnaud\n \nL\n\n, \n\nBae\n \nSC\n\n, \n\n\n. \nEULAR recommendations for the management of systemic lupus erythematosus: 2023 update\n. \nAnn Rheum Dis\n. \n2024;\n83\n(1):\n15\u201329\n. \nhttps:\/\/doi.org\/10.1136\/ard-2023-224762"},{"issue":"(1):","key":"CIT0001","series-title":"Semin Arthritis Rheum","first-page":"43\u20138","article-title":"From incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers","volume":"51","author":"Lambers\n \nWM","year":"2021;","unstructured":"Lambers\n \nWM\n\n, \n\nWestra\n \nJ\n\n, \n\nBootsma\n \nH\n\n, \n\nde Leeuw\n \nK\n\n\n. \nFrom incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers\n. \nSemin Arthritis Rheum\n. \n2021;\n51\n(1):\n43\u20138\n. \nhttps:\/\/doi.org\/10.1016\/j.semarthrit.2020.11.006"},{"issue":"(6):","key":"CIT0002","series-title":"J Clin Investig","first-page":"2228\u201333","article-title":"Mechanisms of human autoimmunity","volume":"125","author":"Rosenblum\n \nMD","year":"2015;","unstructured":"Rosenblum\n \nMD\n\n, \n\nRemedios\n \nKA\n\n, \n\nAbbas\n \nAK\n\n\n. \nMechanisms of human autoimmunity\n. \nJ Clin Investig\n. \n2015;\n125\n(6):\n2228\u201333\n. \nhttps:\/\/doi.org\/10.1172\/JCI78088"},{"issue":"(7):","key":"CIT0003","series-title":"Clin Rheumatol","first-page":"1819\u201326","article-title":"Negative ANA-IIF in SLE patients: what is beyond?","volume":"42","author":"Abozaid\n \nHSM","year":"2023;","unstructured":"Abozaid\n \nHSM\n\n, \n\nHefny\n \nHM\n\n, \n\nAbualfadl\n \nEM\n\n, \n\nIsmail\n \nMA\n\n, \n\nNoreldin\n \nAK\n\n, \n\nEldin\n \nANN\n\n, \n\n\n \nNegative ANA-IIF in SLE patients: what is beyond?\n \nClin Rheumatol\n. \n2023;\n42\n(7):\n1819\u201326\n. \nhttps:\/\/doi.org\/10.1007\/s10067-023-06577-w"},{"issue":"(1):","key":"CIT0004","series-title":"Lupus Sci Med","first-page":"e000635","article-title":"Clinical and histopathological features of myositis in systemic lupus erythematosus","volume":"9","author":"Tiniakou\n \nE","year":"2022;","unstructured":"Tiniakou\n \nE\n\n, \n\nGoldman\n \nD\n\n, \n\nCorse\n \nA\n\n, \n\nMammen\n \nA\n\n, \n\nPetri\n \nMA\n\n\n. \nClinical and histopathological features of myositis in systemic lupus erythematosus\n. \nLupus Sci Med\n. \n2022;\n9\n(1):\ne000635\n. \nhttps:\/\/doi.org\/10.1136\/lupus-2021-000635"},{"key":"CIT0005","series-title":"Arthritis Rheumatol","first-page":"2868\u201370","article-title":"Prevalence and associations of myositis in an Indian inception cohort of lupus","volume":"74","author":"Rajasekhar\n \nL","year":"2022;","unstructured":"Rajasekhar\n \nL\n\n, \n\nShobha\n \nV\n\n, \n\nPonnana\n \nM\n\n, \n\nKavadichanda\n \nC\n\n, \n\nMathew\n \nAJ\n\n, \n\nTripathy\n \nSR\n\n, \n\n\n \nPrevalence and associations of myositis in an Indian inception cohort of lupus\n. \nArthritis Rheumatol\n. \n2022;\n74\n: \n2868\u201370\n."},{"issue":"(10):","key":"CIT0006","series-title":"Br J Rheumatol","first-page":"1067\u201374","article-title":"Clinical features of lupus myositis versus idiopathic myositis: a review of 30 cases","volume":"36","author":"Garton\n \nM","year":"1997;","unstructured":"Garton\n \nM\n\n, \n\nIsenberg\n \nD\n\n\n. \nClinical features of lupus myositis versus idiopathic myositis: a review of 30 cases\n. \nBr J Rheumatol\n. \n1997;\n36\n(10):\n1067\u201374\n. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/36.10.1067"},{"issue":"(4):","key":"CIT0007","series-title":"Eur J Rheumatol","first-page":"148","article-title":"Infections in patients with systemic lupus erythematosus: the contribution of primary immune defects versus treatment-induced immunosuppression","volume":"10","author":"Kunzler\n \nALF","year":"2023;","unstructured":"Kunzler\n \nALF\n\n, \n\nTsokos\n \nGC\n\n\n. \nInfections in patients with systemic lupus erythematosus: the contribution of primary immune defects versus treatment-induced immunosuppression\n. \nEur J Rheumatol\n. \n2023;\n10\n(4):\n148\n. \nhttps:\/\/doi.org\/10.5152\/eurjrheum.2023.23068"},{"issue":"(10):","key":"CIT0008","series-title":"Clin Rheumatol","first-page":"2995\u20133003","article-title":"Evaluation of the 2019 EULAR\/ACR classification criteria for systemic lupus erythematosus in children and adults","volume":"41","author":"Cheng\n \nS","year":"2022;","unstructured":"Cheng\n \nS\n\n, \n\nDing\n \nH\n\n, \n\nXue\n \nH\n\n, \n\nCao\n \nL\n\n\n. \nEvaluation of the 2019 EULAR\/ACR classification criteria for systemic lupus erythematosus in children and adults\n. \nClin Rheumatol\n. \n2022;\n41\n(10):\n2995\u20133003\n. \nhttps:\/\/doi.org\/10.1007\/s10067-022-06293-x"},{"key":"CIT0009","series-title":"Pediatr Rheumatol","first-page":"1\u20138","article-title":"Evaluating the performance of ACR, SLICC and EULAR\/ACR classification criteria in childhood onset systemic lupus erythematosus","volume":"19","author":"Abdwani\n \nR","year":"2021;","unstructured":"Abdwani\n \nR\n\n, \n\nMasroori\n \nE\n\n, \n\nAbdullah\n \nE\n\n, \n\nAl Abrawi\n \nS\n\n, \n\nAl-Zakwani\n \nI\n\n\n. \nEvaluating the performance of ACR, SLICC and EULAR\/ACR classification criteria in childhood onset systemic lupus erythematosus\n. \nPediatr Rheumatol\n. \n2021;\n19\n: \n1\u20138\n. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/keab247.118"},{"issue":"(1):","key":"CIT0010","series-title":"Ann Rheum Dis","first-page":"14\u201325","article-title":"Update on the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis\n \nA","year":"2021;","unstructured":"Fanouriakis\n \nA\n\n, \n\nTziolos\n \nN\n\n, \n\nBertsias\n \nG\n\n, \n\nBoumpas\n \nDT\n\n\n. \nUpdate on the diagnosis and management of systemic lupus erythematosus\n. \nAnn Rheum Dis\n. \n2021;\n80\n(1):\n14\u201325\n. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2020-218272"},{"issue":"(11):","key":"CIT0011","series-title":"Autoimmun Rev","first-page":"102943","article-title":"Systematic review of anti-dsDNA testing for systemic lupus erythematosus: a meta-analysis of the diagnostic test specificity of an anti-dsDNA fluorescence enzyme immunoassay","volume":"20","author":"Orme\n \nME","year":"2021;","unstructured":"Orme\n \nME\n\n, \n\nVoreck\n \nA\n\n, \n\nAksouh\n \nR\n\n, \n\nRamsey-Goldman\n \nR\n\n, \n\nSchreurs\n \nMWJ\n\n\n. \nSystematic review of anti-dsDNA testing for systemic lupus erythematosus: a meta-analysis of the diagnostic test specificity of an anti-dsDNA fluorescence enzyme immunoassay\n. \nAutoimmun Rev\n. \n2021;\n20\n(11):\n102943\n. \nhttps:\/\/doi.org\/10.1016\/j.autrev.2021.102943"},{"issue":"(5):","key":"CIT0012","series-title":"Neuroophthalmology","first-page":"264\u20137","article-title":"Systemic lupus erythematosus presenting as orbital myositis","volume":"38","author":"Jenkins\n \nPO","year":"2014;","unstructured":"Jenkins\n \nPO\n\n, \n\nSoper\n \nC\n\n, \n\nMacKinnon\n \nAD\n\n, \n\nO\u2019Sullivan\n \nE\n\n, \n\nNitkunan\n \nA\n\n\n. \nSystemic lupus erythematosus presenting as orbital myositis\n. \nNeuroophthalmology\n. \n2014;\n38\n(5):\n264\u20137\n. \nhttps:\/\/doi.org\/10.3109\/01658107.2014.923915"},{"issue":"(3):","key":"CIT0013","series-title":"Eur J Rheumatol","first-page":"135\u20137","article-title":"Orbital myositis in systemic lupus erythematosus: a case report and literature review","volume":"7","author":"Chan\n \nAJ","year":"2020;","unstructured":"Chan\n \nAJ\n\n, \n\nRai\n \nAS\n\n, \n\nLake\n \nS\n\n\n. \nOrbital myositis in systemic lupus erythematosus: a case report and literature review\n. \nEur J Rheumatol\n. \n2020;\n7\n(3):\n135\u20137\n \nhttps:\/\/doi.org\/10.5152\/eurjrheum.2020.19217"},{"issue":"(1047):","key":"CIT0014","series-title":"Postgrad Med J","first-page":"59","article-title":"Orbital myositis as manifestation of systemic lupus erythematosus-a case report","volume":"89","author":"Santosa\n \nA","year":"2013;","unstructured":"Santosa\n \nA\n\n, \n\nVasoo\n \nS\n\n\n. \nOrbital myositis as manifestation of systemic lupus erythematosus-a case report\n. \nPostgrad Med J\n. \n2013;\n89\n(1047):\n59\n. \nhttps:\/\/doi.org\/10.2169\/internalmedicine.47.0607"},{"issue":"(8):","key":"CIT0015","series-title":"Intern Med","first-page":"737\u201342","article-title":"Reversible bone marrow dysplasia in patients with systemic lupus erythematosus","volume":"47","author":"Oka\n \nY","year":"2008;","unstructured":"Oka\n \nY\n\n, \n\nKameoka\n \nJ\n\n, \n\nHirabayashi\n \nY\n\n, \n\nTakahashi\n \nR\n\n, \n\nIshii\n \nT\n\n, \n\nSasaki\n \nT\n\n, \n\n\n. \nReversible bone marrow dysplasia in patients with systemic lupus erythematosus\n. \nIntern Med\n. \n2008;\n47\n(8):\n737\u201342\n. \nhttps:\/\/doi.org\/10.2169\/internalmedicine.47.0607"},{"issue":"(2):","key":"CIT0016","series-title":"Hemato","first-page":"329\u201346","article-title":"Inflammatory and immune disorders associated with myelodysplastic syndromes","volume":"2","author":"Jachiet\n \nV","year":"2021;","unstructured":"Jachiet\n \nV\n\n, \n\nFenaux\n \nP\n\n, \n\nSevoyan\n \nA\n\n, \n\nHakobyan\n \nY\n\n, \n\nAdes\n \nL\n\n, \n\nFain\n \nO\n\n, \n\n\n. \nInflammatory and immune disorders associated with myelodysplastic syndromes\n. \nHemato\n. \n2021;\n2\n(2):\n329\u201346\n. \nhttps:\/\/doi.org\/10.3390\/hemato2020019"},{"issue":"(3):","key":"CIT0017","series-title":"Immunology","first-page":"153\u201360","article-title":"Infectious processes and systemic lupus erythematosus","volume":"158","author":"Illescas-Montes\n \nR","year":"2019;","unstructured":"Illescas-Montes\n \nR\n\n, \n\nCorona-Castro\n \nCC\n\n, \n\nMelguizo-Rodr\u00edguez\n \nL\n\n, \n\nRuiz\n \nC\n\n, \n\nCostela-Ruiz\n \nVJ\n\n\n. \nInfectious processes and systemic lupus erythematosus\n. \nImmunology\n. \n2019;\n158\n(3):\n153\u201360\n. \nhttps:\/\/doi.org\/10.1111\/imm.13103"},{"issue":"(1):","key":"CIT0018","series-title":"Ann Rheum Dis","first-page":"15\u201329","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis\n \nA","year":"2024;","unstructured":"Fanouriakis\n \nA\n\n, \n\nKostopoulou\n \nM\n\n, \n\nAndersen\n \nJ\n\n, \n\nAringer\n \nM\n\n, \n\nArnaud\n \nL\n\n, \n\nBae\n \nSC\n\n, \n\n\n. \nEULAR recommendations for the management of systemic lupus erythematosus: 2023 update\n. \nAnn Rheum Dis\n. \n2024;\n83\n(1):\n15\u201329\n. \nhttps:\/\/doi.org\/10.1136\/ard-2023-224762"}],"container-title":["Qatar Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2025\/2\/article-65.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2025\/2\/article-65.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2025\/2\/article-65.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:17:18Z","timestamp":1777310238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2025\/2\/article-65.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":36,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.5339\/qmj.2025.65","relation":{},"ISSN":["2227-0426"],"issn-type":[{"value":"2227-0426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}